Literature DB >> 1616849

Cisplatin and its analogues in the treatment of advanced breast cancer: a review.

I E Smith1, D C Talbot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1616849      PMCID： PMC1977765          DOI： 10.1038/bjc.1992.169

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  38 in total

1.  Phase II study of carboplatin in advanced breast cancer: preliminary results.

Authors:  M Martin; E Diaz-Rubio; A Casado; J M López Vega
Journal:  Semin Oncol       Date:  1991-02       Impact factor: 4.929

2.  Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer.

Authors:  H Y Yap; P Salem; G N Hortobagyi; G P Bodey; A U Buzdar; C K Tashima; G R Blumenschein
Journal:  Cancer Treat Rep       Date:  1978-03

3.  Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research.

Authors:  G Cocconi; G Bisagni; M Bacchi; C Boni; R Bartolucci; G Ceci; M A Colozza; V De Lisi; R Lottici; A M Mosconi
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

4.  Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II study.

Authors:  J D Bitran; M F Kozloff; R K Desser
Journal:  Cancer Invest       Date:  1990       Impact factor: 2.176

5.  Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules.

Authors:  A A Forastiere; T B Hakes; J T Wittes; R E Wittes
Journal:  Am J Clin Oncol       Date:  1982-06       Impact factor: 2.339

6.  High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.

Authors:  S Ostrow; M Egorin; J Aisner; N Bachur; P H Wiernik
Journal:  Cancer Clin Trials       Date:  1980

7.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer.

Authors:  K Kolarić; A Roth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Cyclophosphamide, adriamycin, and cis-platinum (CAP) in metastatic and locally advanced breast cancer.

Authors:  C Verusio; E Bajetta; L Ferrari; C Bartoli; P Valagussa; G Bonadonna
Journal:  Am J Clin Oncol       Date:  1988-08       Impact factor: 2.339

10.  cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study.

Authors:  K Kolarić; R Tomek
Journal:  Tumori       Date:  1990-10-31
View more
  11 in total

1.  A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes.

Authors:  Qiao Li; Qing Li; Pin Zhang; Peng Yuan; Jiayu Wang; Fei Ma; Yang Luo; Ying Fan; Ruigang Cai; Binghe Xu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells.

Authors:  Liping Xu; Shuping Yin; Sanjeev Banerjee; Fazlul Sarkar; Kaladhar B Reddy
Journal:  Mol Cancer Ther       Date:  2011-01-20       Impact factor: 6.261

3.  The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in guinea pigs.

Authors:  T Saito; Z J Zhang; Y Manabe; T Ohtsubo; H Saito
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

4.  Optical molecular imaging approach for rapid assessment of response of individual cancer cells to chemotherapy.

Authors:  Zhen Luo; Rohan Vijay Tikekar; Kiana Michelle Samadzadeh; Nitin Nitin
Journal:  J Biomed Opt       Date:  2012-10       Impact factor: 3.170

5.  Different apoptotic effects of [Pt(O,O'-acac)(γ-acac)(DMS)] and cisplatin on normal and cancerous human epithelial breast cells in primary culture.

Authors:  Carla Vetrugno; Antonella Muscella; Francesco Paolo Fanizzi; Luca Giulio Cossa; Danilo Migoni; Sandra Angelica De Pascali; Santo Marsigliante
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

6.  Visualizing inhibition of nucleosome mobility and transcription by cisplatin-DNA interstrand crosslinks in live mammalian cells.

Authors:  Guangyu Zhu; Lina Song; Stephen J Lippard
Journal:  Cancer Res       Date:  2013-05-21       Impact factor: 12.701

7.  Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.

Authors:  A Urruticoechea; C D Archer; L A Assersohn; R K Gregory; M Verrill; R Mendes; G Walsh; I E Smith; S R D Johnston
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

8.  Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.

Authors:  Zining Jin; Wenqian Wang; Nan Jiang; Lei Zhang; Yiming Li; Xiaoyin Xu; Shouliang Cai; Liang Wei; Xuhong Liu; Guanglei Chen; Yizhen Zhou; Cheng Liu; Zhan Li; Feng Jin; Bo Chen
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

9.  Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents.

Authors:  Dong Wha Jun; Mihwa Hwang; Hyun Jung Kim; Soo Kyung Hwang; Sunshin Kim; Chang-Hun Lee
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

10.  Renal Medulla is More Sensitive to Cisplatin than Cortex Revealed by Untargeted Mass Spectrometry-Based Metabolomics in Rats.

Authors:  Pei Zhang; Jia-Qing Chen; Wan-Qiu Huang; Wei Li; Yin Huang; Zun-Jian Zhang; Feng-Guo Xu
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.